Dave Ricks became CEO of Eli Lilly in 2017, but has been working at different departments within the company since 1996. The last few years have certainly been turbocharged.

Eli Lilly's chief executive, chairman and president John Lechleiter is to step down in December, and will be replaced David Ricks, who currently leads the company’s bio-medicines division.

In an episode of "The David Rubenstein Show: Peer to Peer Conversations," CEO Dave Ricks talks about how the company will begin studies this year to see if its weight-loss medicines can also be ...